鹭燕医药股份有限公司 关于公司股票交易异常波动的公告

Group 1 - The company's stock price experienced an abnormal fluctuation, with a cumulative increase of over 20% in closing prices over two consecutive trading days (January 7 and January 8, 2026) [2] - The company confirmed that there are no corrections or supplements needed for previously disclosed information, and the recent operational situation remains normal without significant changes in the internal or external business environment [2] - The company has not identified any undisclosed significant information that may have impacted its stock price, and there are no undisclosed major matters related to the company by the controlling shareholders or actual controllers [2][3] Group 2 - The board of directors confirmed that there are no matters that should have been disclosed according to the Shenzhen Stock Exchange's listing rules that have not been disclosed, nor any related planning, discussions, or agreements [3] - The company emphasizes that it adheres to fair information disclosure practices and reminds investors to refer to designated media for accurate information [4][5]